ReportGem ReportGem

U.S. COMPANY FILING

REGENERON PHARMACEUTICALS, INC. — Form 10-Q filed 2026-07-30

Filed: 2026-07-30Company: REGENERON PHARMACEUTICALS, INC.Ticker: REGNExchange: NasdaqForm: 10-QReport period: 2026-06-30SEC accession: 0000872589-26-000025Event: earningsMateriality: 85

Filing text preview

Regeneron's Q2 2026 revenue rose 17% to $4.29B, driven by EYLEA HD and Libtayo growth and higher Sanofi collaboration revenue. Net income fell 7% to $1.30B, with diluted EPS of $12.23. Gross margin declined to 78% due to temporary manufacturing interruption. Dividend of $0.94 per share declared.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-07-30Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy2026-08-20FDA Approves Regeneron's (REGN) Pasatru for Ultra-Rare FOP in August 2026; Shares Up 5.4%2026-08-208-K2026-07-30 · 8-K10-Q2026-04-29 · 10-Q8-K2026-04-29 · 8-K10-K2026-02-04 · 10-K8-K2026-01-30 · 8-K